Oxford – October 14, 2026 -- Brainomix has partnered with the Pulmonary Fibrosis Foundation (PFF) to test how patients and caregivers respond when its FDA-cleared, CE-marked e-Lung quantitative CT analysis is built into clinicians' assessment workflow for pulmonary fibrosis (PF) and other fibrotic interstitial lung diseases (ILD).
Patient research targets how CT metrics shape treatment conversations
The multi-phase initiative will examine how objective quantitative CT metrics could improve clinicians' understanding of disease change over time. It will also assess how patients experience and understand those insights.
The partners will explore what patients want to know about their disease, how they respond to visual and quantitative outputs, and where e-Lung may add the most value across their care. A further focus is how imaging-derived insights could inform discussions on whether to start, continue or change treatment, particularly when disease changes are not evident from symptoms alone.
PFF contributes its patient community and Care Center Network
The PFF will draw on its patient and caregiver community and its understanding of the clinical and lived experience of pulmonary fibrosis. Through its Care Center Network, it also connects medical centers with expertise in diagnosing and treating fibrotic lung diseases and in patient-oriented research.
Programme extends the PROGRESS-PPF collaboration with Boehringer Ingelheim
The work is part of PROGRESS-PPF, a broader research initiative between Brainomix and Boehringer Ingelheim. That initiative is exploring whether quantitative CT imaging tools can provide objective metrics to support clinicians assessing disease progression in patients with progressive pulmonary fibrosis. The PFF collaboration adds the patient perspective to that effort.
Brainomix 360 e-Lung provides automatic quantifications and visualizations of radiographic features in lung CT scans. Clinicians can use the outputs to aid diagnostic assessment of lung diseases.
Dr. Michalis Papadakis, CEO and Co-Founder of Brainomix, said the company needs to understand how the tools inform clinical understanding and how that information is communicated to patients. Scott Staszak, President and CEO of the PFF, said the partnership will help establish what information patients find valuable and how it can support conversations with their healthcare teams.